Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 13,584 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Completed Phase 2 Interventional

SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma

NCT00002860
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Surgery
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
124
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Study: Lifting and Tightening of the Elbows

NCT01708382
View directory record Official record
Conditions
Skin Laxity
Interventions
Ulthera System Treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 22, 2026, 5:26 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss

NCT06926023
View directory record Official record
Conditions
Female Pattern Baldness
Interventions
1550nm non-ablative fractional laser, 1927 thulium fractional laser
Device
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 22, 2026, 5:26 AM EDT
Recruiting Not applicable Interventional

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

NCT02945579
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast Irradiation
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Solution in Subjects With Common Warts.

NCT02669862
View directory record Official record
Conditions
Common Warts
Interventions
A-101 Solution 40, A-101 Solution 45, Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 22, 2026, 5:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

NCT06826196
View directory record Official record
Conditions
Alopecia Areata (AA)
Interventions
ALD-102 Solution, Placebo or Control
Drug · Other
Lead sponsor
Aldena Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Thousand Oaks, California • West Lafayette, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 5:26 AM EDT
Active, not recruiting No phase listed Observational

Male Breast Cancer: Understanding the Biology for Improved Patient Care

NCT01101425
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

ICI 182780 in Treating Women With Metastatic Breast Cancer

NCT00012025
View directory record Official record
Conditions
Breast Cancer
Interventions
fulvestrant
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
24
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

NCT05061017
View directory record Official record
Conditions
NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
Interventions
Pixatimod, Nivolumab, Cyclophosphamide (low dose)
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 5:26 AM EDT
Recruiting Not applicable Interventional

Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial

NCT07474090
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Breast Inflammatory Carcinoma, Locally Recurrent Breast Carcinoma
Interventions
Exercise Intervention, Educational Intervention, Supportive Care, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Accelerometry, Electronic Health Record Review, Cardiopulmonary Exercise Testing
Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Phase 4 Interventional Results available

Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study

NCT02147691
View directory record Official record
Conditions
Acne Rosacea
Interventions
Azelaic acid 15%, Brimonidine 0.33%
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Not applicable Interventional Results available

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

NCT00470574
View directory record Official record
Conditions
Breast Cancer
Interventions
QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique, immunologic technique, laboratory biomarker analysis
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Early Phase 1 Interventional

Exercising Our ABC's (African- American Breast Cancer Survivors)

NCT01684579
View directory record Official record
Conditions
Breast Cancer
Interventions
Resistance Exercise, Aerobic Exercise, Behavioral Group Counseling
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 22, 2026, 5:26 AM EDT
Active, not recruiting Phase 2 Interventional Results available

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

NCT02326974
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
T-DM1, Pertuzumab, Excision of tumor/mastectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
4
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 5:26 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rutgers University Study of the Genetics of Breast Cancer.

NCT06773897
View directory record Official record
Conditions
Breast Cancer Risk, Breast Cancer Prevention, Breast Cancer
Interventions
Saliva sample, Health Surveys
Genetic · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

NCT03945760
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Wright State Physicians
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 22, 2026, 5:26 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Impact of the M22-IPL Acne Filter on Acne Vulgaris

NCT02180282
View directory record Official record
Conditions
Acne
Interventions
M22-IPL
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
15 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 22, 2026, 5:26 AM EDT
Recruiting Phase 4 Interventional

A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers

NCT07159282
View directory record Official record
Conditions
Diabetic Foot, Foot Ulcer, Ulcer Foot, DFU, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer Due to Type 1 Diabetes Mellitus, Diabetic Foot Ulcer
Interventions
XWRAP
Other
Lead sponsor
Applied Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 22, 2026, 5:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics

NCT05694559
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer
Interventions
Genetic Testing and Counseling, Screening Form
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

NCT05218642
View directory record Official record
Conditions
Alopecia, Male Pattern Hair Loss
Interventions
KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, Matching placebo to KX-826
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Fountain Valley, California • Hialeah, Florida • Hialeah Gardens, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Phase 3 Interventional Results available

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

NCT01007942
View directory record Official record
Conditions
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
everolimus, Placebo, vinorelbine, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • La Jolla, California • Greenwood Village, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NCT03021460
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 5:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?

NCT01159860
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
cryosurgery, Curettage
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 22, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional Results available

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

NCT00602446
View directory record Official record
Conditions
Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
Interventions
deferasirox
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 22, 2026, 5:26 AM EDT